Additionally, the gastrointestinal tract expresses various Lf receptors; therefore, Lf-added delivery systems have been designed to transport and protect drugs from enzymatic degradation in the intestine favoring the bioavailability to target organs for the treatment of inflammatory bowel disease and colon cancer. This evidence concerns the gene LTF and inflammatory bowel disease.